BRIEF—BlueRock appoints chief scientific officer

Cambridge, Massachusetts-based BlueRock Therapeutics has appointed Seth Ettenberg as chief scientific officer, overseeing R&D efforts based around the firm's proprietary cell and gene platform.

Dr Ettenberg was founding member and CSO at Unum Therapeutics, bringing several novel cellular therapies from invention through to clinical testing. He also headed the Cambridge site of Novartis’ Oncology Biotherapeutics.

Dr Ettenberg said: “Having spent my career advancing disruptive technologies, I am very excited to be joining the team to help realize the full potential of the platform and advance a new wave of therapeutic cellular medicine.”